Raymond James & Associates’s Galmed Pharmaceuticals GLMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-767
| Closed | -$58.9K | – | 3816 |
|
|
2023
Q1 | $58.9K | Hold |
767
| – | – | ﹤0.01% | 3673 |
|
|
2022
Q4 | $69K | Sell |
767
-99
| -11% | -$8.91K | ﹤0.01% | 3642 |
|
|
2022
Q3 | $49K | Sell |
866
-9
| -1% | -$509 | ﹤0.01% | 3661 |
|
|
2022
Q2 | $102K | Sell |
875
-252
| -22% | -$29.4K | ﹤0.01% | 3638 |
|
|
2022
Q1 | $323K | Sell |
1,127
-4
| -0.4% | -$1.15K | ﹤0.01% | 3346 |
|
|
2021
Q4 | $370K | Sell |
1,131
-145
| -11% | -$47.4K | ﹤0.01% | 3298 |
|
|
2021
Q3 | $641K | Buy |
1,276
+121
| +10% | +$60.8K | ﹤0.01% | 2875 |
|
|
2021
Q2 | $632K | Buy |
1,155
+327
| +39% | +$179K | ﹤0.01% | 2909 |
|
|
2021
Q1 | $511K | Buy |
828
+48
| +6% | +$29.6K | ﹤0.01% | 2983 |
|
|
2020
Q4 | $437K | Sell |
780
-490
| -39% | -$275K | ﹤0.01% | 2889 |
|
|
2020
Q3 | $807K | Sell |
1,270
-1,700
| -57% | -$1.08M | ﹤0.01% | 2299 |
|
|
2020
Q2 | $2.56M | Buy |
2,970
+1,058
| +55% | +$910K | ﹤0.01% | 1573 |
|
|
2020
Q1 | $1.19M | Sell |
1,912
-330
| -15% | -$206K | ﹤0.01% | 1864 |
|
|
2019
Q4 | $2.33M | Buy |
2,242
+829
| +59% | +$863K | ﹤0.01% | 1735 |
|
|
2019
Q3 | $1.22M | Buy |
1,413
+780
| +123% | +$671K | ﹤0.01% | 2072 |
|
|
2019
Q2 | $838K | Buy |
633
+148
| +31% | +$196K | ﹤0.01% | 2322 |
|
|
2019
Q1 | $713K | Buy |
485
+6
| +1% | +$8.82K | ﹤0.01% | 2403 |
|
|
2018
Q4 | $589K | Buy |
479
+77
| +19% | +$94.7K | ﹤0.01% | 2443 |
|
|
2018
Q3 | $984K | Buy |
+402
| New | +$984K | ﹤0.01% | 2264 |
|